Authors
Latest:
Registries and the Future of MedicinePayers, providers, patients and pharma companies all want to understand the value of specific treatments – and patient registries can help them do that.
Latest:
Real-time Data Tracking in the Clinical Trial Supply ChainGood Distribution Practice means that ‘track and trace’ is becoming indispensable for drug product integrity. Interactive Response Technologies may offer a potential solution.
Latest:
Brexit and the UK Pharma IndustryEleanor Biggs looks at the biggest uncertainties facing the pharma industry if the UK were to leave the EU.
Latest:
Investing in Patient-Centric Capabilities Requires a Clear StrategyFor those willing to invest in the right capabilities, offering patient services can give pharma companies a tremendous opportunity.
Latest:
Mining Cancer Kryptonite from Historic Clinical Trial DataClinical trial data from completed trials are now beginning to be shared through a variety of channels. While skeptics remain, evidence is growing that this data can lead to practice-changing behavior in patient care.
Latest:
A Digital Prescription for the Pharma IndustryHow companies can better integrate valuable data across business functions to meet rising value-chain demands.
Latest:
A Digital Prescription for the Pharma IndustryHow companies can better integrate valuable data across business functions to meet rising value-chain demands.
Latest:
A Digital Prescription for the Pharma IndustryHow companies can better integrate valuable data across business functions to meet rising value-chain demands.
Latest:
A Digital Prescription for the Pharma IndustryHow companies can better integrate valuable data across business functions to meet rising value-chain demands.
Latest:
A New Era for Market Access: Organizing the Function’s Broader Strategic RoleBCG’s 2022 benchmark study uncovers new competencies needed for pharma access leaders in enterprise-wide business strategy, where thoughtfully designed approaches and goals focused on shared priority and responsibility are increasingly important.
Latest:
Measuring Pharma’s Trust PerformanceThe core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.
Latest:
What is Required of Drug Safety During the COVID-19 PandemicIt is essential to ensure the safety profiles of potential COVID-19 therapies are supported by robust data so that healthcare providers and physicians can make appropriate, evidence-based decisions, writes Dr. Andrew Rut.
Latest:
'PRIME' Time for Medicines in the EUA look at how Europe's new accelerated drug approval scheme can evolve existing review pathways for the better-and take a page from FDA
Latest:
Tackling the Trust IssuePharma's challenge is to break the cycle of mistrust so that its pioneering work can fully reach patients in need, writes GSK's Murray Stewart.
Latest:
Swerving the Talent TrapHighly skilled pharma staff are obliged to devote hours to routine administrative tasks updating product information. Technology can free them from this burden, writes Dr. Jutta Hohenhörst.
Latest:
Realizing the Potential of Asia-PacificCompanies that want to tap into the full potential of Asia-Pac must boost the role of their regional headquarters.
Latest:
“Have We Met Your Needs Today?” Patient Centricity is So Much More than a Customer Satisfaction SurveyIn the healthcare industry, “patient centricity” is like comfort food – everyone knows what it is, but it can mean very different things to different people.
Latest:
Beyond the Buzzword: Finding Your Patient CentricitySponsored contentThe term “patient centric” has become an almost catch-all term. Cheryl Lubbert looks at the broad range of its application. A review of how patient centricity is being applied shows that it is all of these things and more. A look at just a few different uses of the term shows the broad range of its application:
Latest:
FDA's Helping Hand to Small PharmaFDA's Brenda Stodart outlines the services of the Agency's Small Business and Industry Assistance (SBIA) Program.
Latest:
Brexit Report: What's Next for the Industry?As the UK exits the European Union, the pharmaceutical and life sciences industries should prepare for changes by identifying key business issues, mitigating risks and creating plans for multiple scenarios.
Latest:
Expedite Regulated Documents in the Era of COVID-19: From Development to Trials and ManufacturingTechnology is more critical than ever to help you keep your clinical trials on track during the era of COVID-19. Gain best practices about how to empower your remote workforce, get critical regulated documents electronically signed compliantly, and to create a safe and flexible remote patient-centric experience. Live: Wednesday, Jul. 15, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Jul. 15, 2021. Register free
Latest:
UK Biopharma: Life After BrexitPaul Ranson examines how the UK biopharma must now adapt to a changing landscape.
Latest:
Life Sciences' Shifting Sands: 5 Trends that Threaten the Status QuoIf pharma companies want to hold their own in the current climate, they must embrace rather than resist market change.
Latest:
Cuozzo v Lee: How Many Bites at the Apple are Enough?Having lobbied hard to have Inter Partes Review proceedings (IPRs) enacted, the tech industry may now be regretting what it wished for, write Traci Medford-Rosow and Peter C. Richardson.
Latest:
The ‘Cure’-All for 21st Century Data SharingBalancing today’s health data demands and patient privacy is not about new regulations-it’s taking a risk-based approach.
